We spoke with a key Merck executive about the strategy for its top cancer drug, a $7 billion powerhouse that could soon bring in more than $20 billion

Posted by on June 6, 2019 2:08 am
Categories: Business

Back in 2011, when US drug giant Merck was first testing out an innovative new cancer drug in humans, the team knew it was on to something because patients’ cancers responded quickly to the treatment.
So the Merck team started building an ambitious road ma…
Read More